Alta Partners Investments & Fund Profile

Overview

Venture capital firm investing in healthcare and life sciences.

Founded

1996

Deals · 12mo

1

Links

Website LinkedIn X (Twitter)

Stage focus

Series A

Series B

Series C

Geographic focus

United States

Sector focus

Finance

Financial Services

Venture Capital

Investment portfolio

84rounds

LedParticipated

NAME	DATE	SIZE
KymaThera	Oct 2026Led	$80 MSeries B
Harbor Health	Sep 2025Led	$130 MOther Equity
Be Biopharma	Jan 2025Participated	$92 MSeries C
TransMedics	Nov 2024Participated	$30 MSeries C
Be Biopharma	Oct 2024Participated	$82 MOther Equity
EGenesis	Sep 2024Participated	$191 MSeries D
Progentos Therapeutics	May 2024Participated	$65 MSeries A
Transcarent	May 2024Participated	$126 MSeries D
Edgewood Oncology	Mar 2024Led	$20 MSeries A
Harbor Health	Jan 2024Participated	$96 MOther Equity
Lassen Therapeutics	Dec 2023Participated	$85 MSeries B
MBrace Therapeutics	Nov 2023Participated	$85 MSeries B
KymaThera	Oct 2026Led	$80 MSeries B
Harbor Health	Sep 2025Led	$130 MOther Equity
Be Biopharma	Jan 2025Participated	$92 MSeries C
TransMedics	Nov 2024Participated	$30 MSeries C
Be Biopharma	Oct 2024Participated	$82 MOther Equity
EGenesis	Sep 2024Participated	$191 MSeries D
Progentos Therapeutics	May 2024Participated	$65 MSeries A
Transcarent	May 2024Participated	$126 MSeries D
Edgewood Oncology	Mar 2024Led	$20 MSeries A
Harbor Health	Jan 2024Participated	$96 MOther Equity
Lassen Therapeutics	Dec 2023Participated	$85 MSeries B
MBrace Therapeutics	Nov 2023Participated	$85 MSeries B

84 Items

84

Items

...

Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Alta Partners: 84 funding rounds are recorded in the selected participation categories. All available history
Round type	Led deals	Participated deals
Series A	5	10
Series B	3	16
Series C+	4	22
Other Equity	5	19

Monthly Deal Activity

Alta Partners: 84 deals are recorded across 236 months. All available history
Month	Deals
Mar '07	2
Apr '07	1
May '07	2
Jun '07	1
Jul '07	0
Aug '07	1
Sep '07	0
Oct '07	0
Nov '07	0
Dec '07	0
Jan '08	0
Feb '08	0
Mar '08	0
Apr '08	0
May '08	0
Jun '08	0
Jul '08	1
Aug '08	0
Sep '08	0
Oct '08	0
Nov '08	0
Dec '08	0
Jan '09	0
Feb '09	0
Mar '09	0
Apr '09	0
May '09	0
Jun '09	0
Jul '09	1
Aug '09	0
Sep '09	0
Oct '09	0
Nov '09	0
Dec '09	0
Jan '10	0
Feb '10	0
Mar '10	0
Apr '10	1
May '10	0
Jun '10	2
Jul '10	4
Aug '10	1
Sep '10	0
Oct '10	3
Nov '10	2
Dec '10	0
Jan '11	1
Feb '11	2
Mar '11	1
Apr '11	0
May '11	0
Jun '11	0
Jul '11	1
Aug '11	0
Sep '11	0
Oct '11	0
Nov '11	0
Dec '11	1
Jan '12	0
Feb '12	0
Mar '12	0
Apr '12	0
May '12	1
Jun '12	0
Jul '12	0
Aug '12	0
Sep '12	0
Oct '12	1
Nov '12	2
Dec '12	2
Jan '13	0
Feb '13	0
Mar '13	0
Apr '13	1
May '13	2
Jun '13	0
Jul '13	0
Aug '13	0
Sep '13	0
Oct '13	1
Nov '13	0
Dec '13	2
Jan '14	0
Feb '14	1
Mar '14	2
Apr '14	0
May '14	0
Jun '14	0
Jul '14	1
Aug '14	0
Sep '14	1
Oct '14	0
Nov '14	0
Dec '14	0
Jan '15	0
Feb '15	0
Mar '15	0
Apr '15	0
May '15	0
Jun '15	0
Jul '15	0
Aug '15	0
Sep '15	0
Oct '15	0
Nov '15	0
Dec '15	0
Jan '16	0
Feb '16	0
Mar '16	0
Apr '16	0
May '16	0
Jun '16	0
Jul '16	0
Aug '16	0
Sep '16	0
Oct '16	0
Nov '16	0
Dec '16	0
Jan '17	0
Feb '17	0
Mar '17	2
Apr '17	0
May '17	0
Jun '17	0
Jul '17	0
Aug '17	0
Sep '17	1
Oct '17	0
Nov '17	0
Dec '17	1
Jan '18	0
Feb '18	0
Mar '18	0
Apr '18	0
May '18	0
Jun '18	0
Jul '18	1
Aug '18	1
Sep '18	0
Oct '18	1
Nov '18	0
Dec '18	0
Jan '19	0
Feb '19	0
Mar '19	0
Apr '19	0
May '19	1
Jun '19	0
Jul '19	0
Aug '19	0
Sep '19	0
Oct '19	0
Nov '19	1
Dec '19	0
Jan '20	2
Feb '20	0
Mar '20	0
Apr '20	0
May '20	0
Jun '20	2
Jul '20	0
Aug '20	0
Sep '20	0
Oct '20	1
Nov '20	0
Dec '20	0
Jan '21	0
Feb '21	1
Mar '21	2
Apr '21	0
May '21	0
Jun '21	2
Jul '21	0
Aug '21	0
Sep '21	0
Oct '21	0
Nov '21	0
Dec '21	0
Jan '22	1
Feb '22	0
Mar '22	0
Apr '22	3
May '22	0
Jun '22	0
Jul '22	1
Aug '22	0
Sep '22	1
Oct '22	0
Nov '22	1
Dec '22	0
Jan '23	0
Feb '23	0
Mar '23	0
Apr '23	0
May '23	0
Jun '23	0
Jul '23	0
Aug '23	0
Sep '23	0
Oct '23	0
Nov '23	2
Dec '23	1
Jan '24	1
Feb '24	0
Mar '24	1
Apr '24	0
May '24	2
Jun '24	0
Jul '24	0
Aug '24	0
Sep '24	1
Oct '24	1
Nov '24	1
Dec '24	0
Jan '25	1
Feb '25	0
Mar '25	0
Apr '25	0
May '25	0
Jun '25	0
Jul '25	0
Aug '25	0
Sep '25	1
Oct '25	0
Nov '25	0
Dec '25	0
Jan '26	0
Feb '26	0
Mar '26	0
Apr '26	0
May '26	0
Jun '26	0
Jul '26	0
Aug '26	0
Sep '26	0
Oct '26	1

Sector Breakdown

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Alta Partners: Health & Life Sciences is the largest displayed sector by deal count (84 deals). All available history
Sector	Deals
Health & Life Sciences	84
Fintech	4
Networks, Cloud & Communication	1
Manufacturing	1
Data, Analytics & IT	1
Space & Frontier Tech	1

Deal Size Distribution

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Alta Partners: 84 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)	Deals
<$5M	0
$5M-$10M	3
$10M-$25M	18
$25M-$50M	31
$50M-$100M	20
$100M-$250M	12
$250M-$500M	0
$500M-$1B	0
$1B+	0

Deals By Geography

Top 2 of 2 regions; European countries are grouped as Europe.

Alta Partners: United States has the largest recorded deal count among the displayed regions (81 deals). All available history
Region	Deals
United States	81
Europe	3

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Alta Partners: 20 co-investors are shown, with ARCH Venture Partners sharing 9 recorded deals. All available history
Co-investor	Shared deals
ARCH Venture Partners	9
Longwood Fund	8
New Enterprise Associates	8
RA Capital Management	8
RiverVest Venture Partners	7
Venrock	7
Atlas Venture	5
Frazier Healthcare Partners	5
General Catalyst	5
Leaps by Bayer	5
Polaris Partners	5
Questa Capital	5
Roche Venture	5
Alexandria Venture Investments	4
Amgen Ventures	4
Domain Associates	4
Khosla Ventures	4
Lilly Ventures	4
Merck	4
MPM Capital	4